Publications

Filters
February 27, 2024

First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma

Read more
January 31, 2024

Debio 0123, a selective, brain penetrant WEE1 inhibitor in clinical development for patients with solid tumors

Read more
December 10, 2023

Debio 1562M, a next generation Antibody Drug Conjugate (ADC) targeting CD37 for AML and MDS treatment

Read more
November 17, 2023

A Phase 1/2 study of the WEE1 inhibitor Debio 0123 in combination with temozolomide +/– radiotherapy in adults with recurrent…

Read more
November 13, 2023

The Multilink(TM) Linker is a promising approach to improve efficacy and safety of ADC’s

Read more
June 9, 2023

Evaluation of the microbiota-sparing properties of the anti-staphylococcal antibiotic afabicin

Read more
June 3, 2023

First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CAIX-expressing tumors

Read more
June 3, 2023

Debio 0123-101, a phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors: safety, pharmacokinetic, and…

Read more
April 19, 2023

Debio 0123 is a selective WEE1 inhibitor that effectively penetrates the brain and demonstrates anti-tumor activity in preclinical models of…

Read more